Re: The financial impact of delays to percutaneous nephrolithotomy surgery at a county hospital

The manuscript by Palasi et al.[1] provides a comprehensive analysis of the financial and healthcare utilization impacts associated with delays in percutaneous nephrolithotomy (PCNL) surgery within a county hospital setting. This study is, particularly, timely and relevant, given the increasing incidence of renal stone disease and the ongoing challenges posed by healthcare access disparities.

Contemporary research underscores the substantial economic burden of nephrolithiasis. The overall cost of nephrolithiasis treatments has nearly doubled over recent years, with the total expenditure in the United States projected to reach $4.1 billion by 2030[2,3]. This increase is driven by the rising prevalence of kidney stones and the associated healthcare costs, including emergency department visits, inpatient care, and surgical interventions[3].

The costs vary significantly depending on the treatment modality. For instance, retrograde intrarenal surgery is generally the least expensive, followed by extracorporeal shockwave lithotripsy, PCNL, and open surgery[1]. The economic efficiency of these treatments is a critical consideration, especially in managing large and complex stones, where PCNL is often preferred despite its higher costs[3].

The financial burden of nephrolithiasis extends beyond direct medical costs. Patients often face significant financial toxicity, which includes both direct and indirect costs, such as loss of workdays and out‐of‐pocket expenses[3]. Studies have shown that one episode of nephrolithiasis requiring hospitalization can result in substantial work loss, further exacerbating the economic impact on patients[4]. This financial strain can adversely affect patients' quality of life and their ability to afford necessary medical care[5].

1 KEY FINDINGS

1.1 Increased financial burden

The study highlights a significant increase in hospital charges correlated with delays in PCNL surgery. Patients experiencing delays of over 6 months faced 36% higher hospital charges compared to those treated within 4 months. This finding underscores the economic strain on both patients and the healthcare system due to prolonged waiting times.

1.2 Healthcare utilization

Delays in surgery were associated with increased preoperative healthcare utilization, including more frequent computed tomography scans, clinic visits, and procedural interventions. This not only elevates costs but also suggests a higher burden on healthcare resources and staff.

1.3 Impact on medically underserved populations

The study focuses on a medically underserved population, revealing that delays are more pronounced in this group. Factors such as insurance status and minority background contribute to longer waiting times, highlighting the need for targeted interventions to address these disparities.

1.4 COVID‐19 pandemic effects

The manuscript also touches on the exacerbating effects of the COVID‐19 pandemic on surgical delays, providing a broader context for the observed trends. This aspect is crucial for understanding the compounded challenges faced by healthcare systems during global health crises.

2 STRENGTHS AND LIMITATIONS

The study's strengths lie in its robust retrospective design and detailed financial analysis, which provide valuable insights into the cost implications of surgical delays. However, the single‐center nature of the study and the retrospective data collection pose limitations regarding the generalizability of the findings. Future research should aim to include multicenter data and prospective designs to validate and expand upon these results.

3 CONCLUSION

Palasi et al.'s work is a significant contribution to the field of urology, emphasizing the critical need for timely surgical interventions to mitigate financial and healthcare burdens. The findings advocate for policy changes and resource allocation to reduce delays in PCNL surgery, particularly for underserved populations. This manuscript serves as a call to action for healthcare providers and policymakers to address the systemic issues contributing to surgical delays and to improve overall patient outcomes.

References

[1] Palasi SF, Rivas A, Owen CK, Rajendran R, Macias J, Gregg J, et al. The financial impact of delays to percutaneous nephrolithotomy surgery at a county hospital. UroPrecision. 2024;2:127–133.

[2] Chung KJ, Kim JH, Min GE, Park HK, Li S, Del Giudice F, et al. Changing trends in the treatment of nephrolithiasis in the real world. J Endourol. 2019;33(3):248–253.

[3] Roberson D, Sperling C, Shah A, Ziemba J. Economic considerations in the management of nephrolithiasis. Curr Urol Rep. 2020;21(5):18.

[4] Green BW, Labagnara K, Feiertag N, Gupta K, Donnelly J, Watts KL, et al. Financial toxicity of nephrolithiasis: the first assessment of the economic stresses of kidney stone treatment. Urology. 2022;170:46–52.

[5] Setia SA, Gelikman DG, Cabo J, Hsi RS. Patient‐reported financial toxicity associated with management of nephrolithiasis. Urology. 2023;174:52–57.

RIGHTS & PERMISSIONS

2024 The Author(s). UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.